Hello! You're looking at a policy document report on Overton

We track government policy, guidelines, think tank research, working papers and more to help our customers see the impact and influence of their work. Are you interested in seeing what information we have to offer? Request a free trial to our platform.

If you fund, produce or manage research or work to influence policy, we'd love to talk. Learn more on our homepage.

Medicare Part B: Expenditures for New Drugs Concentrated among a Few Drugs, and Most Were Costly for Beneficiaries

U.S. Government Accountability Office on November 20th 2015

New Medicare Part B drugs were more likely than new drugs not paid under Part B to be biologics, that is, products derived from living sources; be approved to treat a narrower range of conditions; and to have used a Food and Drug Administration (FDA) program to expedite their development and review.

See the 23 policy documents that cite this document

See report on the 23 policy documents that cite this document

Topics in this document

Pharmaceutical sciences New Drug Application Clinical trial Food and Drug Administration Priority review Drug development Orphan drug Biopharmaceutical Phases of clinical research Fast track (FDA) Government Accountability Office Health care Pharmacy Health Medical specialties Drugs Health sciences Health policy Pharmacology Clinical medicine Medicine Medical treatments Healthcare industry Medicare (United States) Breakthrough therapy Federal Food, Drug, and Cosmetic Act Medical research Cancer Medicinal chemistry Medicare Part D

Related SDGs

Citations

Cited by 23 other policy documents (20 of them are from other policy sources)

overton